サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：エピネフリン自己注射器の世界市場-2022-2029
市場調査レポート
商品コード
1140753

エピネフリン自己注射器の世界市場-2022-2029

Global Epinephrine Autoinjector Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 170 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
エピネフリン自己注射器の世界市場-2022-2029
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 170 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

アナフィラキシーの症例増加と自己投与薬の需要増が市場成長の原動力となっています。

アナフィラキシーは、毒物、食物、薬物に対する重度のアレルギー反応です。多くは、蜂に刺されたり、ピーナッツや木の実などアレルギーを引き起こすことが知られている食品を食べたりすることで起こります。アナフィラキシーの一般的な原因には、薬、ピーナッツ、木の実、虫刺され、魚、貝、牛乳などがあります。その他の原因としては、運動やラテックスなどが考えられます。アナフィラキシーが疑われる場合、エピネフリン溶液をできるだけ早く、大腿外側面の中央部、つまり米国の広背筋の位置に相当する部分に筋肉内注射をします。National Library of Medicineによると、米国市民の1.6％から5.1％がアナフィラキシーを経験していると推定されています。PubMedなどの臨床データベースは、アナフィラキシーの有病率の上昇を捉えています。したがって、アナフィラキシーの発生率の増加は、応急処置の選択肢であるエピネフリンの高い使用率を高め、世界市場を牽引するものと考えられます。薬物注射器の使用と廃棄が容易になったことで、自動注射器の販売機会も生まれています。このことは、市場の成長を後押ししています。

しかし、注射の代替手段が複数あることと、継続的な進歩が市場成長の妨げになると予想されます。

地理的浸透度。

予測期間中、北米が圧倒的な地域となっています。

北米は、2021年の世界のエピネフリン自己注射器市場で最大の市場シェアを占めています。同地域では、いくつかのエピネフリン自己注射器が発売されています。後発品もあります。それぞれがエピネフリンという薬物を含んでいます。しかし、各デバイスは独自の使用説明書を持っています。その違いを理解することは、自分の欲しい機器を手に入れ、正しい使い方を知るために不可欠なことです。重篤なアレルギーを持つ子どもたちは、EpiPenおよびEpiPen Jr.エピネフリン自己注射器の新しいジェネリック医薬品を地域で入手することができます。2022年8月、サノフィは、Auvi-Qと名付けられた生命を脅かすアレルギーを持つ患者のための最初の音声ガイド付きエピネフリン自己注射器のFDA承認を発表しました。同社は、インテリジェクト社からAuvi-Qの北米における商業化権をライセンスされており、その他の地域の商業化権はインテリジェクト社が保持しています。

競合情勢。

世界のエピネフリン自己注射器市場における主要企業には、ALK-Abello A/S、Amneal Pharmaceuticals Inc、Adamis Pharmaceuticals Corporation、Kaleo Inc、Mylan N.V、Novartis International AG、Pfizer Inc、Teva Pharmaceutical Industries Ltd.等が含まれます。市場参加者は、市場シェアを獲得するために、費用対効果の高い堅牢なソリューションの開拓に取り組んでいます。主要プレイヤーは、製品の発売、買収、提携など、いくつかの成長戦略を採用しており、エピネフリン自己注射器市場の世界の成長に貢献しています。2022年2月、サノフィはAmunixの買収を完了しました。この買収により、Amunix社のPro-XTEN、XPAT、XPAC技術にアクセスし、次世代の条件付活性化生物製剤を提供することができます。また、この買収により、T細胞エンゲージャーとサイトカイン療法に関する有望なパイプラインが追加されます。2022年1月、AmnealはSaol TherapeuticsのBaclofenフランチャイズ（非公開の専門製薬会社）を買収しました。この買収は、Amnealの神経学における商業機関および専門ポートフォリオを拡大する一方、バイオシミラー機関市場への参入に先立ち、商業インフラを追加するものです。

COVID-19の影響。世界のエピネフリン自己注射器市場にネガティブな影響を与えます。

COVID-19は、生産と需要に直接影響を与え、サプライチェーンを乱し、市場を混乱させ、企業や金融市場に財務的な影響を与えることで、世界経済に影響を及ぼします。ほとんどの国で戸締り規制が緩和されていますが、コロナウイルス（COVID-19）の拡散を恐れて、人々は直接医師を訪問することを躊躇しています。したがって、エピネフリン自己注射器市場の企業は、COVID-19時代に個人が遠隔ヘルスケアサービスを好むので、遠隔医療を採用しています。遠隔医療技術の需要は、予測期間中に劇的に上昇するでしょう。

世界のエピネフリン自己注射器市場レポートでは、約64の市場データ表、53の図、170ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 用法用量別市場内訳
  • 年齢層別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 患者の利便性に対する要求の高まり
    • 抑制要因
      • 代替ドラッグデリバリーモードへの嗜好性
    • 市場機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析
  • 保険償還分析
  • アンメットニーズ分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 投与量別

  • 0.15mgエピネフリン自己注射器
  • 0.3mgエピネフリン自己注射器
  • 0.5mgエピネフリン自己注射器

第8章 年齢層別

  • 6歳未満
  • 6歳以上12歳未満
  • 12歳以上

第9章 エンドユーザー別

  • 病院
  • クリニック
  • 個人

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Mylan Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • ALK-Abello AS
  • Adamis Pharmaceuticals Corp.
  • Amneal Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amedra Pharmaceuticals LLC
  • Sanofi Sa
  • Lincoln Medical Ltd
  • Antares Pharma Inc.
  • Novartis AG
  • Pfizer Inc.（Hospira Inc.）（List Not Exhaustive）

第13章 DataM

目次
Product Code: DMPH2877

Market Overview

Epinephrine Autoinjector Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Epinephrine (adrenaline) is a medicine used to treat conditions such as asthma, cardiac arrest, superficial bleeding, and anaphylaxis. It can also be used by inhalation for croup. Epinephrine autoinjectors are hand-held devices carried by those with severe allergies; the epinephrine delivered by the device is an emergency treatment for an anaphylactic reaction. Epinephrine autoinjector is also called EpiPen; a device used to inject a measured dose of adrenaline by autoinjector technology. The device is capable of intramuscular injection for instant and better results. The pen is designed specifically to avoid accidental punctures in the skin, as the syringe is enclosed under a protected shield and needs to operate manually to inject when kept on the patient's skin. The global Epinephrine Autoinjector Market growth is driven by several factors, such growing prevalence of allergies and their awareness among customers, increasing advancement in the product with cost-effective solutions, and rising demand for autoinjectors instead of traditional syringes.

Market Dynamics: Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex. When anaphylaxis is suspected, epinephrine solution is given as soon as possible as an intramuscular injection in the middle of the outer side of the thigh, which corresponds to the location of the vast us lateral muscle. According to the national library of medicine, between 1.6% and 5.1% of US citizens are estimated to have experienced anaphylaxis. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it is the first-aid treatment option, thereby driving the global market. Ease of usage and disposal of drug injectors has created opportunities for autoinjectors. This, in turn, is boosting the market's growth.

However, multiple alternatives for injections and continuous advancements are expected to hamper the market growth.

Market Segmentation: The 0.3mg epinephrine auto-injector segment is projected to be the dominant segment in the market during the forecast period.

Based on dosage, the market is segmented into 0.15mg epinephrine auto-injector, 0.3mg epinephrine auto-injector, and 0.5mg epinephrine auto-injector.

The 0.3mg epinephrine auto-injector accounted for the largest market share due to its various applications across all age groups and moderate doses, among others. The growth of this segment is expected to have an exponential rise during the forecast period. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. The prevalence of food allergies is high in children. Various studies have shown the majority of food allergy incidences, including anaphylaxis, occur in schools or daycare centres. Hence, epinephrine auto-injectors are considered an integral part of emergency care in schools and daycare centres.

The rising incidence of anaphylaxis in the adults & elderly is a primary factor driving the growth of the 0.5mg epinephrine auto-injector dose segment. Epinephrine is considered the first-line treatment for anaphylaxis. In addition, market players are focusing on providing generic, low-cost products. This is raising the demand for affordable treatment options for managing anaphylactic reactions.

Based on Age Group, the age group 6-12 years segment is expected to held significant market share in the fastest CAGR over the forecast period.

The age group 6-12 years children are more prone to anaphylaxis and are currently experiencing the leading position in the market and are expected to grow significantly in the forecast period. However, the prevalence of anaphylaxis is increasing in the geriatric population and is expected to grow at a considerable pace. The burden of anaphylaxis among children is growing, which requires quick and effective management. The government and regulatory bodies are giving safeguards to prevent fatal reactions among children in the 6-12 years of age group. The epinephrine, through auto-injectors, acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it has always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

Geographical Penetration: North America is the dominating region during the forecast period.

North America accounted for the largest market share of the global epinephrine autoinjector market in 2021. Several epinephrine autoinjectors are now available in the region. There are generic versions as well. Each contains the drug epinephrine. But, each device possesses its own unique set of instructions for use. Understanding the differences are essential to get the device one wants and knowing how to use it properly. Children with severe allergies now have access to a new generic version of EpiPen and EpiPen Jr. Epinephrine autoinjectors in the region. In August 2022, Sanofi Announces FDA Approval for its first voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies named, Auvi-Q. The company has licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

Competitive Landscape:

Some of the major players in the global epinephrine autoinjector market include ALK-Abello A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Epinephrine Autoinjector Market globally. In February 2022, Sanofi completed the acquisition of Amunix. This acquisition provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next-generation Conditionally Activated Biologics. Also, this acquisition adds a promising pipeline of T-cell engagers and cytokine therapies. In January 2022, Amneal acquired Saol Therapeutics' Baclofen Franchise, a private specialty pharmaceutical company. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.

COVID-19 Impact: Negative impact on the global epinephrine autoinjector market.

COVID-19 affects the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and having a financial impact on firms and financial markets. Most countries have relaxed lockdown regulations, but people are reluctant to visit doctors in person due to the fear of spreading coronavirus (COVID-19). Thus, companies in the epinephrine autoinjector market are adopting telemedicine as individuals prefer remote healthcare services during the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period.

The global epinephrine autoinjector market report would provide an access to approximately 64 market data tables, 53 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Dosage
  • 3.2. Market Snippet by Age Group
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Convenience of Patients
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Preference for Alternative Drug Delivery Modes
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Dosage

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Segment
  • 7.3. Market Attractiveness Index, By Dosage Segment
    • 7.3.1. 0.15mg Epinephrine Autoinjector*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. 0.3mg Epinephrine Autoinjector
    • 7.3.3. 0.5mg Epinephrine Autoinjector

8. By Age Group

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
  • 8.3. Market Attractiveness Index, By Age Group Segment
    • 8.3.1. Under 6 Years Patients*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. 6 to 12 Years Patients
    • 8.3.3. Over 12 Years Patients

9. By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Individuals

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Mylan Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. ALK-Abello AS
  • 12.3. Adamis Pharmaceuticals Corp.
  • 12.4. Amneal Pharmaceuticals Inc.
  • 12.5. Teva Pharmaceutical Industries Ltd.
  • 12.6. Amedra Pharmaceuticals LLC
  • 12.7. Sanofi Sa
  • 12.8. Lincoln Medical Ltd
  • 12.9. Antares Pharma Inc.
  • 12.10. Novartis AG
  • 12.11. Pfizer Inc.( Hospira Inc.) (List Not Exhaustive)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us